Peroxiredoxin 1 inhibits tumorigenesis by activating the NLR family pyrin domain containing 3/gasdermin D pathway: Advanced therapies targeting heterogeneous cell death mechanisms

doi:10.3748/wjg.v31.i44.114404

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 44

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (529)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

159

Sum=192

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

235

Sum=302

Nov 28, 2025 (publication date) through Mar 4, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastroenterol. Nov 28, 2025; 31(44): 114404
Published online Nov 28, 2025. doi: 10.3748/wjg.v31.i44.114404

Peroxiredoxin 1 inhibits tumorigenesis by activating the NLR family pyrin domain containing 3/gasdermin D pathway: Advanced therapies targeting heterogeneous cell death mechanisms

Anna Smirnova, Daria Eygel, Irina Kondrasheva, Denis S Baranovskii, Ilya D Klabukov

Anna Smirnova, Daria Eygel, Irina Kondrasheva, Denis S Baranovskii, Ilya D Klabukov, Department of Regenerative Medicine, National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk 249036, Russia

Anna Smirnova, Ilya D Klabukov, Obninsk Institute for Nuclear Power Engineering of the National Research Nuclear University MEPhI, Obninsk 249033, Russia

Irina Kondrasheva, Department of Regenerative Dentistry, Tsiolkovsky Kaluga State University, Kaluga 248023, Russia

Denis S Baranovskii, Institute of Systems Biology and Medicine, Russian University of Medicine, Moscow 127006, Russia

Author contributions: Klabukov ID designed and performed the research, and wrote the letter; Baranovskii DS analyzed the data; Smirnova A, Kondrasheva I, and Eygel D revised the letter.

Supported by Russian Science Foundation, No. 24-64-00028.

Conflict-of-interest statement: There are no conflicts of interest to report.

Corresponding author: Ilya D Klabukov, PhD, Director, Department of Regenerative Medicine, National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, No. 4 Koroleva Street, Obninsk 249036, Russia. ilya.klabukov@gmail.com

Received: September 18, 2025
Revised: September 30, 2025
Accepted: October 22, 2025
Published online: November 28, 2025
Processing time: 71 Days and 12.5 Hours

Core Tip

Core Tip: The molecular patterns of the special types of programmed cell death, such as apoptosis, pyroptosis, ferroptosis, and necroptosis, in cancer cells caused by altered regulation, could improve the effectiveness of mRNA vaccines and targeted therapies by overcoming the barrier function of the tumor microenvironment. Activation of specific pathways to overcome the barrier function in cancer treatment represents a promising strategy for targeted cellular and gene therapies, and also enhances radiosensitivity in radiation therapy.